Efeitos Adversos Cutâneos das Terapêuticas Dirigidas e Inibidores dos Checkpoints Immunológicos em Doentes com Melanoma
Resumo
A terapêutica dirigida e a imunoterapia melhoraram significativamente o prognóstico dos doentes com melanoma avançado. Por outro lado, a expansão destes fármacos levou ao aumento do espetro de efeitos adversos cutâneos. Embora a maioria das reações seja de baixo grau, muitas causam morbilidade considerável, com forte impacto na qualidade de vida dos doentes. O diagnóstico precoce e a intervenção atempada poderão evitar a descontinuação dos tratamentos oncológicos. Neste artigo, revemos os efeitos adversos cutâneos das pequenas moléculas e anticorpos monoclonais usados no tratamento do melanoma, assim como a sua fisiopatologia e abordagem terapêutica.
Downloads
Referências
Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021;141:23-31. doi: 10.1016/j.jid.2020.03.943.
Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435-48. doi: 10.1016/j.annonc.2020.07.004.
Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1449-61. doi: 10.1016/j.annonc.2020.07.005.
Boada A, Carrera C, Segura S, Collgros H, Pasquali P, Bodet D, et al. Cutaneous toxicities of new treatments for melanoma. Clin Transl Oncol. 2018;20:1373-84. doi:10.1007/s12094-018-1891-7.
Hwang SJ, Anforth R, Carlos G, Fernandez-Peñas P. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. Actas Dermosifiliogr. 2017;108:6-16. doi:10.1016/j.ad.2016.05.019.
Gnanendran SS, Turner LM, Miller JA, Hwang SJE, Miller AC. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. Curr Treat Options Oncol. 2020;21:29. doi:10.1007/s11864-020-0721-7.
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248-60. doi:10.1016/S1470-2045(16)30122-X.
Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, et al. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers. 2020;12:482. doi:10.3390/cancers12020482.
Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangan J, et al. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. J Eur Acad Dermatol Venereol. 2019;33:686-92. doi:10.1111/jdv.15363.
Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172:239-43. doi:10.1111/bjd.13200.
Lacouture M, Sibaud V. toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31-9. doi:10.1007/s40257-018-0384-3.
Boull CL, Gardeen S, Abdali T, Li E, Potts J, Rubin N, et al. Cutaneous Reactions in Children Treated with MEK Inhibitors, BRAF Inhibitors, or Combination Therapy: A Multi-Center Study. J Am Acad Dermatol. 2020 (in press). doi:10.1016/j.jaad.2020.07.044.
Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013;169:1310-3. doi: 10.1111/bjd.12519.
Chon SY, Sambrano BL, Geddes ER. Vemurafenib-related cutaneous side effects ameliorated by acitretin. J Drugs Dermatol. 2014;13:586-8.
Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4:e000491. doi:10.1136/esmoopen-2019-000491.
Zhao CY, Hwang SJE, Wakade D, Carlos G, Anforth R, Fernández-Peñas P. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. Australas J Dermatol. 2017;58:292-8. doi:10.1111/ajd.12645.
Anforth RM, Carlos GR, Scolyer RA, Chou S, Fernandez-Peñas P. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Res. 2015;25:91-4. doi:10.1097/CMR.0000000000000127.
Deutsch A, Balagula Y, McLellan BN. Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature. J Am Acad Dermatol. 2020 (in press). doi:10.1016/j.jaad.2020.04.074.
Onnis G, Palmieri G, Montesu MA, Satta R. Second primary melanoma on a patient undergoing vemurafenib therapy. A case report. Int J Dermatol. 2017;56:792-4. doi:10.1111/ijd.13445.
Heppt MV, Clanner-Engelshofen BM, Marsela E, Wessely A, Kammerbauer C, Przybilla B, et al. Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. Photodermatol Photoimmunol Photomed. 2020;36:126-34. doi:10.1111/phpp.12520.
Eberlein B, Biedermann T, Hein R, Posch C. Vemurafenib-related photosensitivity. J Dtsch Dermatol Ges. 2020 (in press). doi:10.1111/ddg.14140.
Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15:249-59. doi:10.1007/s11912-013-0308-6.
Ferreira J, Toda-Brito H, Moura MC, Sachse MF, Costa-Rosa J. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature. J Cutan Pathol. 2017;44:307-9. doi:10.1111/cup.12857.
Vance SL, Singer HM, Silvers D, Husain S, Kabigting F. Delayed-onset vemurafenib-induced panniculitis. JAAD Case Rep. 2017;3:384-6. doi:10.1016/j.jdcr.2017.06.001.
Richarz NA, Puig L, Pérez N, Cuadra-Urteaga J, Elez E, Fernández-Figueras MT. Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. Cancer Biol Ther. 2019;20:237-9. doi:10.1080/15384047.2018.1529113.
Hui Ong EL, Sinha R, Jmor S, Fearfield L. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases. Am J Dermatopathol. 2019;41:214-7. doi:10.1097/DAD.0000000000001276.
Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019;7:4. doi:10.1186/s40425-018-0475-y.
Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55:250-4. doi:10.1111/ajd.12124.
Habre M, Salloum A, Habre SB, Abi Chebl J, Dib R, Kourie HR. Skin adverse events in recently approved targeted therapies in solid malignancies. Future Oncol. 2019;15:331-43. doi:10.2217/fon-2018-0402.
Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Future Oncol. 2015;11:3307-19. doi:10.2217/fon.15.265.
Wang CJ, Brownell I. BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors. Am J Clin Dermatol. 2020 (in press). doi:10.1007/s40257-020-00539-7.
Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, et al. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130:1417-30. doi:10.1172/JCI128678.
Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:e181-9. doi:10.1016/S1470-2045(14)71133-7.
Plachouri KM, Georgiou S. Therapeutic approaches to pyogenic granuloma: an updated review. Int J Dermatol. 2019;58:642-8. doi:10.1111/ijd.14268.
Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, et al. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017;8:83280-91. doi:10.18632/oncotarget.21059.
Pires E, Moura C. Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors. J Port Soc Dermatol Venereol. 2018;76:47-52. doi:10.29021/spdv.76.1.868
Pires E, Moura C. Immune Checkpoint Inhibitors in Melanoma: Review and Update.. J Port Soc Dermatol Venereol. 2018;76:237-52. doi:10.29021/spdv.76.3.970
Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DY, Moy AP, et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse. J Am Acad Dermatol. 2020 (in press). doi:10.1016/j.jaad.2020.03.132.
Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [published online ahead of print, 2020 Aug 3]. J Cutan Med Surg. doi:10.1177/1203475420943260.
Lu J, Thuraisingam T, Chergui M, Nguyen K. Nivolumab-associated DRESS syndrome: A case report. JAAD Case Rep. 2019;5(3):216-218. doi:10.1016/j.jdcr.2018.11.017.
Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017;27:271-3. doi:10.1097/CMR.0000000000000326.
Logan IT, Zaman S, Hussein L, Perrett CM. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review. J Immunother. 2020;43:89-92. doi:10.1097/CJI.0000000000000302.
Cohen BE, Manga P, Lin K, Elbuluk N. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences . Am J Clin Dermatol. 2020 (in press).doi:10.1007/s40257-020-00524-0.
Ramondetta A, Ribero S, Conti L, Fava P, Marra E, Broganelli P, et al. Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors. Acta Derm Venereol. 2020;100:adv00001. doi:10.2340/00015555-3319.
Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, et al. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019;46:627-36. doi: 10.1111/cup.13454.
Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger MS, Barysch M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018;28:230-6. doi:10.1097/CMR.0000000000000437.
Hwang SJE, Park JJW, Wakade D, Chou S, Byth K, Fernandez-Penas P. Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Res. 2019;29:172-7. doi:10.1097/CMR.0000000000000518.
McArthur GA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S et al. CT012 e Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: primary results from the phase 3 IMspire150
trial. AACR Virtual. Annual Meeting. April 27e28, 2020.
Direitos de Autor (c) 2021 Revista da Sociedade Portuguesa de Dermatologia e Venereologia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Todos os artigos desta revista são de acesso aberto sob a licença internacional Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0).
